|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 31/451 | (2006.01) |
| A61K 31/706 | (2006.01) | ||
| A61K 31/7068 | (2006.01) | ||
| A61P 35/02 | (2006.01) |
| (11) | Number of the document | 3068393 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14805743.3 |
| Date of filing the European patent application | 2014-11-11 | |
| (97) | Date of publication of the European application | 2016-09-21 |
| (45) | Date of publication and mention of the grant of the patent | 2022-03-09 |
| (46) | Date of publication of the claims translation | 2022-08-10 |
| (86) | Number | PCT/US2014/065034 |
| Date | 2014-11-11 |
| (87) | Number | WO 2015/070224 |
| Date | 2015-05-14 |
| (30) | Number | Date | Country code |
| 201361902717 P | 2013-11-11 | US |
| (72) |
CAENEPEEL, Sean , US
CANON, Jude , US
HUGHES, Paul , US
OLINER, Jonathan D. , US
RICKLES, Richard J. , US
SAIKI, Anne Y. , US
|
| (73) |
Amgen Inc. ,
One Amgen Center Drive, Thousand Oaks, California 91320-1799,
US
|
| (74) |
Aušra PAKĖNIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Kombinuota terapija, įskaitant MDM2 inhibitorių ir vieną arba daugiau papildomų farmaciškai aktyvių agentų, skirta vėžiui gydyti |
| COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS |
| Payment date | Validity (years) | Amount | |
| 2022-11-21 | 9 | 312.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2023-11-11 |